CELLTRION

Celltrion is a manufacturing company. It is a biopharmaceutical firm, not a trading company.

Celltrion Introduction

Celltrion Inc. is a leading South Korean biopharmaceutical company headquartered in Incheon, South Korea. Established in 2002, the company specializes in the research, development, and manufacturing of biosimilar drugs and novel biologics. Celltrion operates extensive manufacturing facilities and laboratories, focusing on producing high-quality, affordable biotherapeutic medicines. Its primary business areas include immunology, oncology, and other therapeutic fields. Celltrion is globally recognized for its innovations in the biosimilar market, aiming to enhance patient access to advanced medical treatments.

Here are the products manufactured or sold by Celltrion, categorized for clarity:

**Biosimilars:**

* Remsima (Infliximab biosimilar)

* Truxima (Rituximab biosimilar)

* Herzuma (Trastuzumab biosimilar)

* Vegzelma (Bevacizumab biosimilar)

* Yuflyma (Adalimumab biosimilar)

**Novel Drugs:**

* Remsima SC (Subcutaneous formulation of Infliximab)

* Zymfentra (Remsima SC in the US market)

**Pharmaceuticals (Small Molecules & Others):**

* Various generic and over-the-counter (OTC) medications, including those for liver disease, hypertension and influenza treatment

**COVID-19 Treatment:**

* Regkirona (Regdanvimab) - COVID-19 antibody treatment